Injectable hyaluronic acid for the correction of HIV-associated facial lipoatrophy.
OBJECTIVE
To evaluate the use of Perlane, an injectable form of hyaluronic acid, for the correction of HIV-associated facial lipoatrophy.


METHODS
A prospective, observational study in a consecutive series of 18 HIV-positive males with facial lipoatrophy injected with Perlane. Fourteen patients were available for final analysis.


RESULTS
Mean follow-up time was 12 months. Based on photographic analysis, there was a significant early improvement (P = 0.0035). This difference remained significant after 12 months (P = 0.04666); no significant difference in grade was shown between 1 and 12 months (P = 0.3693). Office assessments of improvement showed an early marked improvement in 85.8% of patients, and 78.6% of subjects demonstrated at least moderate improvement at 12 months.


CONCLUSIONS
Patient satisfaction was high, with only minor side effects and no late complications. Our findings support Perlane to be a feasible option for the provisional correction of mild to moderate facial lipoatrophy.
Denton
Andrew B
AB
Department of Otolaryngology, University of British Columbia, Vancouver, British Columbia, Canada.
Tsaparas
Yotis
Y
D000328:Adult; D005150:Facial Hemiatrophy / Q000139:chemically induced / Q000628:therapy*; D015658:HIV Infections / Q000188:drug therapy; D039682:HIV-Associated Lipodystrophy Syndrome / Q000628:therapy*; D006801:Humans; D006820:Hyaluronic Acid / Q000008:administration & dosage*; D007267:Injections; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies
C502935:Perlane; D006820:Hyaluronic Acid